Table 5 The role of lncRNAs in regulating EZH2 in different cancers
From: The long and short non-coding RNAs modulating EZH2 signaling in cancer
LncRNA | Signaling network | Cancer type | Remarks | References |
|---|---|---|---|---|
NEAT1 | ALKBH/NEAT1/EZH2 | Gastric cancer | Overexpression of ALKBH in cancer cells and tissues Demethylation of NEAT1 for its activation Upregulation of EZH2 and enhancing cancer progression | [328] |
TSPEAR-AS2 | BTEB2/TSPEAR-AS2/EZH2/GJA1 | Gastric cancer | Upregulation of lncRNA by BTEB2 Driving cancer progression via enhancing EZH2 expression and down-regulating GJA1 | [329] |
TRERNA1 | EZH2/CDH1 | Gastric cancer | Enhancing cancer metastasis via upregulating EZH2 and subsequent inhibition of CDH1, leading to EMT induction | [330] |
SNHG6 | EZH2/miRNA-101-3p/ZEB1 | Gastric cancer | Transcriptional inhibition via recruiting EZH2 Inducing EMT via miRNA-101-3p down-regulation and subsequent stimulation of ZEB1 expression Increasing cancer metastasis | [331] |
LINC00460 | EZH2/LSD1/CCNG2 | Gastric cancer | Overexpression of lncRNA in cancerous tissues compared to normal tissues Inducing EZH2/LSD1 axis to down-regulate CCNG2 expression Enhancing cancer progression | [332] |
HOXA11-AS | MiRNA-1297/EZH2 | Gastric cancer | Reducing miRNA-1297 expression via sponging Inducing EZH2 expression and its complex formation with histone demethylase LSD1 or DNMT1 Increasing cancer cell growth | [333] |
FOXP4-AS1 | EZH2/LSD1 | Gastric cancer | Facilitating proliferation and metastasis of cancer cells Inducing EZH22/LAS1 axis | [334] |
P21 | EZH2/STAT3 | Prostate cancer | Increased transcription of lncRNA p21 by enzalutamide through activating androgen signaling Activating non-histone methyltransferase activity of EZH2 STAT3 methylation and subsequent induction of NED | [335] |
MALAT1 | – | Prostate cancer | Recruitment of EZH2 and enhancing its tumorigenesis activity | [336] |
MALAT1 | EZH2/Notch1 | Esophageal cancer | Inducing EZH2/Notch1 axis to promote metastasis via EMT induction | [337] |
HERES | EZH2/Wnt | Esophageal squamous cell carcinoma | Interaction of HERES with EZH2 through G-quadruple structure-like motif Activating Wnt signaling Enhancing growth, migration and colony formation capacity of cancer cells | [338] |
CASC9 | EZH2/PDCD4 | Esophageal squamous cell carcinoma | Association with poor survival of cancer patients Increasing cancer growth Enriching EZH2 Reducing PDCD4 expression after binding of EZH2 to its promoter | [339] |
HOXA-AS2 | EZH2/LSD1 | Pancreatic cancer | Increasing cancer growth and survival Apoptosis inhibition Enhancing cell cycle progression Inducing EZH2/LSD1 axis | [340] |
AGAP2-AS1 | RREB1/AGAP-AS1/EZH2 | Pancreatic cancer | Overexpression of lncRNA by RREB1 Transcriptional repression of ANKRD1 and ANGPTL4 to activate EZH2 signaling Increasing cancer progression and metastasis | [341] |
BLACAT1 | EZH2/CDKN1C | Pancreatic cancer | BLACAT1 recruits EZH2 to provide trimethylation of CDKN1C promoter via H3K27 Enhancing proliferation and inducing glycolysis | [342] |
HOTAIRM1 | HOXA1/EZH2 | Glioblastoma multiforme | Upregulation of HOXA1 by HOTAIRM1 Demethylation and sequestering EZH2 Increasing cancer proliferation and metastasis | [343] |
LINC00115 | TGF-β/LINC00115/EZH2 | Glioma | MiRNA-200s down-regulation by TGF-β-mediated LINC00115 upregulation Inducing ZNF596 transcription Triggering EZH2/STAT3 axis for cancer progression | [344] |
PVT1 | EZH2/Hippo/Notch1 | Non-small cell lung cancer | PVT1 stimulates Hippo/Notch1 axis via upregulating EZH2 Increasing cancer metastasis | [345] |
FOXC2 | EZH2/p15 | Non-small cell lung cancer | Apoptosis inhibiting Preventing cell cycle arrest P53 down-regulation via activating EZH2 signaling | [346] |
UCA1 | EZH2/CDKN1A | Non-small cell lung cancer | Epigenetic silencing of CDKN1A via recruiting EZH2 Enhancing proliferation and inhibiting apoptosis | [347] |
PVT1 | MiRNA-526b/EZH2 | Non-small cell lung cancer | Association with poor prognosis Down-regulation of miRNA-526b and subsequent induction of EZH2 | [348] |
MSTO2P | – | Lung cancer | Enhancing EZH2 expression and promoting proliferation and invasion of cancer cells | [228] |
HOTAIR | – | Lung cancer | Silencing HOTAIR/EZH2 axis increases potential of atractylenolide 1 and erlotinib in lung cancer suppression | [349] |
HOTAIR | – | Breast cancer | Apoptosis inhibition Inducing cell cycle progression Increasing cancer proliferation EZH2 recruitment Increasing DNA repair Inducing radio-resistance | [350] |
TUG1 | EZH2/miRNA-194-5p/CCND2 | Bladder cancer | Recruiting EZH2 to down-regulate miRNA-194-5p Inhibiting CCND2 expression Silencing TUG1 increases cisplatin sensitivity of cancer cells | [351] |
SPRY4-IT1 | MiRNA-101-3p/EZH2 | Bladder cancer | Increasing cancer proliferation and metastasis Reducing miRNA-101-3p expression via sponging Increasing EZH2 expression | [352] |
AWPPH | EZH2/Smad4 | Bladder cancer | Recruitment of EZH2 by AWPPH Subsequent upregulation of Smad4 and enhancing cancer proliferation and progression | [353] |
CACS15 | EZH2/APC | Ovarian cancer | Overexpression of CACS15 is associated with poor survival of cancer patients Increasing proliferation and metastasis Recruiting EZH2 to promoter of APC to inhibit it | [354] |
SUMO1P3 | EZH2/CPEB3 | Colorectal cancer | Apoptosis inhibition and increasing proliferation upon SUMO1P3 overexpression Recruiting EZH2 to promoter of CREB3 Epigenetic repression of CREB3 by EZH2 | [355] |
DUXAP8 | EZH2/LSD1 | Colorectal cancer | DUXAP8 enhances EZH2 and LSD1 levels in providing cancer progression Association with tumor size and tumor grade | [356] |
LL22NC03-N64E9.1 | EZH2/KLF2 | Colorectal cancer | Enhancing cancer proliferation and colony formation capacities Apoptosis inhibition Exerting carcinogenesis impact LncRNA binds to EZH2 to down-regulate KLF4 and provide its tumorigenesis impact | [357] |
MALAT1 | MiRNA-363-3p/EZH2 | Colorectal cancer | Down-regulating miRNA-363-3p via sponging Inducing EZH2 signaling Enhancing cancer progression in vitro and in vivo | [358] |
FAM83C | EZH2/SEMA3F | Colorectal cancer | Promoting malignant transformation of colorectal cancer Stabilizing EZH2 and increasing methylation of SEMA3F | [359] |
SNHG6 | MiRNA-26a/EZH2 | Colorectal cancer | MiRNA-26a inhibition and subsequent upregulation of EZH2 Enhancing metastasis via EMT induction Increasing growth and survival of cancer cells | [341] |
PRADX | EZH2/NF-κB | Colon adenocarcinoma | Recruiting EZH2 by PRADX in promoter of UBXN1 gene NF-κB activation and increasing cancer progression | [360] |
CASC11 | STAT3/CASC11/EZH2/PTEN | Hepatocellular carcinoma | Overexpression of CASC11 by STAT3 Recruiting EZH2 and subsequent down-regulation of PTEN Enhancing cancer migration and invasion via EMT induction | [361] |
HOXD-AS1 | MiRNA-130a-3p/SOX4/EZH2 | Liver cancer | Protecting SOX4 against degradation via miRNA-130a-3p down-regulation Enhancing EZH2 expression and paving the way for cancer progression | [362] |
PVT1 | EZH2/MYC | Liver cancer | Recruitment of EZH2 by PVT1 and subsequent induction of MYC expression Increasing cancer progression | [363] |
SNHG8 | EZH2/RECK | Cervical cancer | Apoptosis inhibition Facilitating proliferation Recruiting EZH2 for transcriptional repression of RECK | [364] |
LINC01535 | MiRNA-214/EZH2 | Cervical cancer | Reverse relationship between LINC01535 and miRNA-214 Inducing EZH2 signaling Promoting growth in vitro and in vivo | [365] |
PVT1 | EZH2/miRNA-200b | Cervical cancer | Binding to EZH2 and recruiting it at promoter of miRNA-200b Enhancing proliferation and migration | [366] |